Annual Current Liabilities
$4.28 M
+$21.00 K+0.49%
01 December 2023
Summary:
NovaBay Pharmaceuticals annual total current liabilities is currently $4.28 million, with the most recent change of +$21.00 thousand (+0.49%) on 01 December 2023. During the last 3 years, it has risen by +$836.00 thousand (+24.29%). NBY annual current liabilities is now -24.78% below its all-time high of $5.69 million, reached on 31 December 2019.NBY Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$1.98 M
-$1.63 M-45.04%
01 September 2024
Summary:
NovaBay Pharmaceuticals quarterly total current liabilities is currently $1.98 million, with the most recent change of -$1.63 million (-45.04%) on 01 September 2024. Over the past year, it has dropped by -$2.29 million (-53.62%). NBY quarterly current liabilities is now -68.27% below its all-time high of $6.25 million, reached on 30 September 2019.NBY Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBY Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -53.6% |
| 3 y3 years | +24.3% | -42.4% |
| 5 y5 years | -24.8% | -65.1% |
NBY Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +24.3% | -67.3% | at low |
| 5 y | 5 years | -24.8% | +51.0% | -67.3% | at low |
| alltime | all time | -24.8% | +1280.0% | -68.3% | +540.0% |
NovaBay Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.98 M(-45.0%) |
| June 2024 | - | $3.61 M(-8.0%) |
| Mar 2024 | - | $3.92 M(-8.3%) |
| Dec 2023 | $4.28 M(+0.5%) | $4.28 M(-6.4%) |
| Sept 2023 | - | $4.57 M(-24.6%) |
| June 2023 | - | $6.07 M(+37.1%) |
| Mar 2023 | - | $4.42 M(+3.9%) |
| Dec 2022 | $4.26 M(+23.7%) | $4.26 M(+14.7%) |
| Sept 2022 | - | $3.71 M(+1.4%) |
| June 2022 | - | $3.66 M(-23.6%) |
| Mar 2022 | - | $4.78 M(+39.0%) |
| Dec 2021 | $3.44 M(+21.5%) | $3.44 M(+19.8%) |
| Sept 2021 | - | $2.87 M(+20.3%) |
| June 2021 | - | $2.39 M(-22.4%) |
| Mar 2021 | - | $3.08 M(+8.7%) |
| Dec 2020 | $2.83 M(-50.2%) | $2.83 M(-5.7%) |
| Sept 2020 | - | $3.00 M(-30.2%) |
| June 2020 | - | $4.30 M(-21.6%) |
| Mar 2020 | - | $5.48 M(-3.6%) |
| Dec 2019 | $5.69 M(+47.8%) | $5.69 M(-9.0%) |
| Sept 2019 | - | $6.25 M(+86.5%) |
| June 2019 | - | $3.35 M(-38.1%) |
| Mar 2019 | - | $5.41 M(+40.7%) |
| Dec 2018 | $3.85 M(-22.7%) | $3.85 M(+13.9%) |
| Sept 2018 | - | $3.38 M(+10.5%) |
| June 2018 | - | $3.06 M(-5.0%) |
| Mar 2018 | - | $3.22 M(-35.4%) |
| Dec 2017 | $4.98 M(+15.2%) | $4.98 M(-5.4%) |
| Sept 2017 | - | $5.26 M(+11.1%) |
| June 2017 | - | $4.74 M(+10.1%) |
| Mar 2017 | - | $4.30 M(-0.5%) |
| Dec 2016 | $4.32 M(-6.7%) | $4.32 M(+16.0%) |
| Sept 2016 | - | $3.73 M(-14.7%) |
| June 2016 | - | $4.37 M(+8.4%) |
| Mar 2016 | - | $4.03 M(-13.1%) |
| Dec 2015 | $4.63 M | $4.63 M(+8.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2015 | - | $4.25 M(+54.1%) |
| June 2015 | - | $2.76 M(-25.3%) |
| Mar 2015 | - | $3.70 M(+10.6%) |
| Dec 2014 | $3.35 M(-7.8%) | $3.35 M(+42.2%) |
| Sept 2014 | - | $2.35 M(+16.7%) |
| June 2014 | - | $2.02 M(-11.6%) |
| Mar 2014 | - | $2.28 M(-37.1%) |
| Dec 2013 | $3.63 M(+14.3%) | $3.63 M(+18.5%) |
| Sept 2013 | - | $3.06 M(+9.8%) |
| June 2013 | - | $2.79 M(+12.7%) |
| Mar 2013 | - | $2.47 M(-22.0%) |
| Dec 2012 | $3.17 M(+11.8%) | $3.17 M(-21.3%) |
| Sept 2012 | - | $4.03 M(+7.7%) |
| June 2012 | - | $3.74 M(+27.6%) |
| Mar 2012 | - | $2.93 M(+3.4%) |
| Dec 2011 | $2.84 M(+4.2%) | $2.84 M(-28.8%) |
| Sept 2011 | - | $3.98 M(+7.3%) |
| June 2011 | - | $3.71 M(-0.5%) |
| Mar 2011 | - | $3.73 M(+37.1%) |
| Dec 2010 | $2.72 M(-32.6%) | $2.72 M(-10.4%) |
| Sept 2010 | - | $3.04 M(+29.0%) |
| June 2010 | - | $2.36 M(-40.2%) |
| Mar 2010 | - | $3.94 M(-2.5%) |
| Dec 2009 | $4.04 M(-9.9%) | $4.04 M(-25.7%) |
| Sept 2009 | - | $5.44 M(+16.0%) |
| June 2009 | - | $4.68 M(-17.7%) |
| Mar 2009 | - | $5.69 M(+27.1%) |
| Dec 2008 | $4.48 M(-2.1%) | $4.48 M(-21.0%) |
| Sept 2008 | - | $5.67 M(+5.4%) |
| June 2008 | - | $5.38 M(-8.7%) |
| Mar 2008 | - | $5.89 M(+28.7%) |
| Dec 2007 | $4.58 M(+35.2%) | $4.58 M(-15.6%) |
| Sept 2007 | - | $5.42 M(+29.2%) |
| June 2007 | - | $4.20 M(-10.2%) |
| Mar 2007 | - | $4.68 M(+38.1%) |
| Dec 2006 | $3.39 M(+992.3%) | $3.39 M(+992.3%) |
| Dec 2005 | $310.00 K | $310.00 K |
FAQ
- What is NovaBay Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for NovaBay Pharmaceuticals?
- What is NovaBay Pharmaceuticals quarterly current liabilities year-on-year change?
What is NovaBay Pharmaceuticals annual total current liabilities?
The current annual current liabilities of NBY is $4.28 M
What is the all time high annual current liabilities for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high annual total current liabilities is $5.69 M
What is NovaBay Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of NBY is $1.98 M
What is the all time high quarterly current liabilities for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals all-time high quarterly total current liabilities is $6.25 M
What is NovaBay Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, NBY quarterly total current liabilities has changed by -$2.29 M (-53.62%)